United Therapeutics (UTHR) Tops Q3 EPS by 120c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Cowen Remains Bullish on United Therapeutics (UTHR) as Orenitram Continues to Grow
October 27, 2015 4:01 PM EDTCowen reiterated an Outperform rating and $185.00 price target on United Therapeutics Corp. (NASDAQ: UTHR) following the company's 3Q15 earnings results. All pulmonary hypertension products beat expectations, driving revenue and EPS above consensus.
Analyst Phil Nadeau commented, "UTHR reported strong Q3 results this morning. All pulmonary... More
Leerink Partners Reiterates Market Perform Following United Therapeutics (UTHR) 3Q beat
October 27, 2015 1:44 PM EDTLeerink Partners reiterated a Market Perform rating and $166.00 price target on United Therapeutics Corp. (NASDAQ: UTHR) following the company's 3Q15 earnings report. UTHR reported 3Q revenues and non-GAAP EPS of $386M and $3.55 that beat Street estimates of $362M and $3.22. Management reported that sales... More
